I am a
Home I AM A Search Login

Papers of the Week


Papers: 25 Jul 2020 - 31 Jul 2020


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Itch


2020 Jul 25


Lancet


396


10246

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

Authors

L Simpson E, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, Bieber T, Thyssen JP, Yosipovitch G, Flohr C, Magnolo N, Maari C, Feeney C, Biswas P, Tatulych S, Valdez H, Rojo R
Lancet. 2020 Jul 25; 396(10246):255-266.
PMID: 32711801.

Abstract

Abrocitinib, an oral selective Janus kinase 1 inhibitor, was effective and well tolerated in adults with moderate-to-severe atopic dermatitis in a phase 2b trial. We aimed to assess the efficacy and safety of abrocitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis.